1373348-57-2

Upstream product

• 19417-23-3 1,1-dideuterio-2-propyn-1-ol 
• 4124-41-8 p-toluenesulfonylanhydride 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1373348-58-3 (2S)-2-{methyl[(1,1-⁽²⁾H₂)prop-2-yn-1-yl]amino}-3-phenyl-propan-1-ol 

Relevant academic research and scientific papers

SYNTHESIS OF BIOCOMPATIBLE TRITYL RADICALS FOR APPLICATIONS AS HYPERPOLARIZATION AGENTS

Described herein are compositions and methods relating to paramagnetic probes for EPR spectroscopy. Compositions and methods as described herein provide for biocompatible paramagnetic probes which can be targeting to a target in vitro or in vivo, and whic

NOVEL KCNQ POTASSIUM CHANNEL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF

The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, conv

15N magnetic resonance hyperpolarization via the reaction of parahydrogen with 15N-Propargylcholine

15N-Propargylcholine has been synthesized and hydrogenated with para-H2. Through the application of a field cycling procedure, parahydrogen spin order is transferred to the 15N resonance. Among the different isomers formed upon hydrogenation of 15N- propargylcholine, only the nontransposed derivative contributes to the observed N-15 enhanced emission signal. The parahydrogen-induced polarization factor is about 3000. The precise identification of the isomer responsible for the observed 15N enhancement has been attained through a retro-INEPT (15N-1H) experiment. T1 of the hyperpolarized 15N resonance has been estimated to be ca. 150 s, i.e., similar to that reported for the parent propargylcholine (144 s). Experimental results are accompanied by theoretical calculations that stress the role of scalar coupling constants (JHN and JHH) and of the field dependence in the formation of the observed 15N polarized signal. Insights into the good cellular uptake of the compound have been gained.

DEUTERIUM ENRICHED RASAGILINE

The subject invention provides deuterated rasagiline, its salts and uses.

COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

This invention relates to novel compounds suitable as precursors for the preparation of certain 18F labelled positron emission tomography (PET) tracers. Furthermore, the invention relates to the preparation of such precursor molecules and to th

Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)

This invention relates to novel compounds suitable as precursors for the preparation of certain 18F labelled positron emission tomography (PET) tracers. Furthermore, the invention relates to the preparation of such precursor molecules and to th

COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

This invention relates to novel compounds suitable for labelling by 18F and the corresponding 18F labelled compounds themselves, 19F-fluorinated analogues thereof and their use as reference standards, methods of preparing